Compare Raymond James Financial, Inc. (RJF) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Summit Therapeutics Inc — how do they compare? Raymond James Financial, Inc. trades at $167 (market cap $32.73B), while Summit Therapeutics Inc trades at $14.75 (market cap $11.34B). The key difference: Raymond James Financial, Inc. is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RJF | SMMT | |
|---|---|---|
Market Cap | $32.73B | $11.34B |
Sector | Financials | Health |
52-Week High | $176.43 | $29.32 |
52-Week Low | $140.89 | $13.05 |
Dividend Yield | 1.29% | — |
Enterprise Value | — | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $167.93, down 0.26% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows strong fundamental performance with 2025 revenue of $13.84B and net income of $2.14B, supported by a P/E of 15.89. Analyst consensus is positive with a $176.83 price target, and recent news highlights advisor recruitment driving growth.
The outlook for RJF remains favorable due to earnings momentum and institutional interest, though risks include expense pressures and market volatility. The stock presents a growth opportunity with solid valuation support, but investors should monitor cost management and macroeconomic factors that could impact financial services performance.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
